Sourcing Guide Contents
Industrial Clusters: Where to Source Adderall Brand Name Manufacturer
SourcifyChina B2B Sourcing Intelligence Report: Critical Clarification & Strategic Guidance
Report Date: October 26, 2026
Prepared For: Global Procurement Managers | Pharmaceutical & Healthcare Sector
Subject: Market Analysis for Sourcing “Adderall Brand Name Manufacturer” from China
Executive Summary: Critical Legal & Regulatory Imperative
This report must begin with an unequivocal statement: There are no legitimate Chinese manufacturers producing or authorized to produce the branded prescription medication “Adderall” (dextroamphetamine/amphetamine salts). Adderall is a Schedule II controlled substance in the United States (DEA) and is subject to equally stringent international and Chinese regulations (PRC Drug Administration Law, CFDA/NMPA regulations).
- Brand Ownership: Adderall is exclusively manufactured and distributed by authorized licensees of Shire plc (now part of Takeda Pharmaceutical Company Limited) in specific, regulated markets (primarily the US). No Chinese entity holds rights to the “Adderall” brand name or formula for global commercial distribution.
- Chinese Regulatory Stance: China strictly controls the production, export, and import of all CNS stimulants (including amphetamines) under the Regulations on the Administration of Precursors for Narcotic Drugs and Psychotropic Substances. Manufacturing finished dosage forms of Schedule II substances like amphetamines for export to markets like the US requires explicit, near-impossible-to-obtain approvals from both Chinese (NMPA) and destination-country (e.g., FDA, DEA) authorities. No Chinese facility is approved to produce Adderall for the US market.
- Market Reality: Any supplier in China claiming to manufacture “Adderall” (brand name or generic equivalent for US/global markets) is operating illegally. This constitutes either:
- Counterfeiting: Producing fake medication (a severe criminal offense).
- Unlicensed API Production: Manufacturing the active pharmaceutical ingredient (API) without authorization for finished drug export (still illegal for controlled substances without specific multi-national licenses).
- Scam Operation: Targeting uninformed buyers.
Procurement managers must treat any such sourcing inquiry as a severe compliance and legal risk. Sourcing controlled substances like Adderall from unauthorized sources, especially outside regulated supply chains, violates international law (e.g., UN Single Convention on Narcotic Drugs), exposes companies to criminal liability, product seizure, massive fines, and reputational ruin.
Strategic Redirect: Legitimate Sourcing Pathways for CNS APIs (Non-Branded, Compliant)
While sourcing branded Adderall is impossible and illegal, procurement managers may have legitimate needs for dextroamphetamine or amphetamine salts API for:
1. Licensed Generic Production: In countries where a local generic version is approved (requiring local manufacturer authorization & regulatory filings).
2. Research Purposes: Strictly for pre-clinical/clinical research under approved protocols and licenses.
SourcifyChina Guidance: Sourcing any controlled substance API requires:
* Proof of Legal Authorization: Valid import/export licenses from both origin and destination countries (e.g., Chinese NMPA Export Certificate, US DEA Importer Registration, Convention on Psychotropic Substances permits).
* Direct Engagement with NMPA-Certified API Manufacturers: Only facilities with specific licenses for controlled substance API production.
* Full Supply Chain Due Diligence: Including GMP certification (China GMP, ideally PIC/S equivalent), anti-diversion measures, and auditable traceability.
Key Industrial Clusters for Pharmaceutical API Manufacturing (General Context – Not Applicable to Adderall Brand)
China has significant pharmaceutical API manufacturing capacity, concentrated in clusters known for chemical and pharma expertise. Crucially, facilities producing controlled substance APIs like amphetamines are extremely rare, highly specialized, and subject to the strictest oversight. General API clusters include:
- Jiangsu Province (Especially Taixing, Nantong, Wuxi): The dominant cluster for complex, regulated APIs. Home to global players (e.g., WuXi AppTec,药明康德 API division, Qilu Pharma) and numerous NMPA/FDA/EMA-approved manufacturers. Strong infrastructure, skilled workforce, stringent environmental controls.
- Zhejiang Province (Especially Hangzhou, Shaoxing, Taizhou): Major hub for chemical intermediates and APIs, strong in antibiotics, vitamins, and some specialty chemicals. Mix of large state-owned and private enterprises. Significant export focus.
- Shandong Province (Especially Weifang, Jinan): Strong in bulk chemicals, fermentation-based APIs (e.g., vitamins, amino acids), and some generic APIs. Cost-competitive, but historically faced more environmental scrutiny.
- Hubei Province (Wuhan): Growing cluster with strong university links (e.g., Wuhan University), focus on newer chemical entities and biotech. Government investment driving growth.
Critical Note for Controlled Substances: Production of Schedule II substances like amphetamines is NOT widespread. Facilities capable and licensed for this are exceedingly few, likely state-affiliated or joint ventures with deep regulatory compliance expertise, and located within the most secure zones of clusters like Jiangsu. They do not produce “Adderall” as a branded product.
Comparative Analysis: Key Pharmaceutical API Production Regions (General API Context Only)
This table illustrates typical differentiators for legitimate, non-controlled substance API sourcing. It does NOT apply to Adderall or other controlled substance finished products. Sourcing controlled substances invalidates standard regional comparisons due to extreme regulatory constraints.
| Factor | Jiangsu Province Cluster | Zhejiang Province Cluster | Shandong Province Cluster |
|---|---|---|---|
| Price | ★★★☆☆ (Higher) Highest labor, environmental compliance, and quality assurance costs. Premium for complex/GMP APIs. |
★★★★☆ (Moderate-High) Competitive, but rising costs. Strong for established generics. |
★★★★★ (Lowest) Historically lower costs, but environmental upgrades increasing prices. Best for bulk/less complex APIs. |
| Quality | ★★★★★ (Highest) Highest concentration of FDA/EMA/PIC/S GMP certified facilities. Strongest focus on complex APIs, stringent QA/QC. Industry benchmark. |
★★★★☆ (High) Many high-quality GMP facilities, especially around Hangzhou. Strong for intermediates & established APIs. Slightly more variance than Jiangsu. |
★★★☆☆ (Moderate) Mix of high-quality (e.g., Qilu) and lower-tier facilities. Strong in fermentation APIs. Environmental compliance historically a bigger challenge. |
| Lead Time | ★★★☆☆ (Moderate) Can be longer due to rigorous QC, documentation, and potential for complex custom synthesis. Very reliable for scheduled production. |
★★★★☆ (Good) Generally efficient, strong logistics. Often faster for standard APIs than Jiangsu. |
★★★★★ (Best) Often quickest for standard, high-volume bulk APIs due to scale and process maturity. |
| Regulatory Strength | ★★★★★ (Exceptional) Deepest experience with stringent int’l regulators (FDA, EMA). Best documentation practices. |
★★★★☆ (Strong) Significant experience, particularly with EU/China regulations. Growing FDA engagement. |
★★★☆☆ (Developing) Improving rapidly, but historically less frequent FDA inspections. Stronger focus on domestic/Asian markets. |
| Best Suited For | Complex, high-value APIs; Regulated markets (US, EU, Japan); Critical quality requirements; Controlled substances if legally authorized (extremely rare). | Established generic APIs; Intermediates; Markets with strong EU/China focus; Cost-sensitive but quality-critical needs. | Bulk APIs; Fermentation-derived APIs; Cost-driven projects for less regulated markets; Vitamin/amino acid APIs. |
SourcifyChina Recommendations & Next Steps
- Immediately Halt Any “Adderall Brand” Sourcing Efforts: This is a non-viable and illegal pathway. Redirect resources to compliant sourcing strategies.
- Verify Legitimate Need & Authorization: If seeking amphetamine salts API:
- Confirm exact legal authorization for import/export in both countries.
- Ensure your own company and the end-user have all required licenses (DEA, NMPA, etc.).
- Engage Specialized Compliance Partners: Work only with:
- Reputable global API distributors with proven controlled substance licensing.
- SourcifyChina’s Regulatory Affairs team (we conduct pre-vetted facility assessments only for clients with verified legal authorization).
- Focus Sourcing on Jiangsu: For any legitimate controlled substance API need requiring Chinese sourcing, Jiangsu is the only plausible cluster due to its concentration of top-tier, regulatorily sophisticated manufacturers. Expect significantly higher costs and longer qualification timelines.
- Conduct Rigorous Due Diligence: Mandatory on-site audits focused specifically on controlled substance handling, security, anti-diversion protocols, and regulatory license verification. Standard GMP audits are insufficient.
- Explore Alternative Licensed Sources: Investigate established generic manufacturers in India (e.g., Sun Pharma, Dr. Reddy’s – if they hold specific authorizations for your target market) or authorized US/EU facilities, which are often the only legally viable routes for Adderall equivalents.
Disclaimer: SourcifyChina strictly adheres to all international and Chinese laws regarding pharmaceuticals and controlled substances. We do not facilitate, endorse, or engage in any activity related to the sourcing of counterfeit medications, unauthorized controlled substances, or branded products outside legitimate patent/licensing frameworks. This report is provided for informational and compliance guidance only. Legal counsel specializing in international pharmaceutical regulation is mandatory before any procurement action involving controlled substances.
SourcifyChina – Ensuring Compliance, Delivering Value in Global Sourcing
Your Trusted Partner in Navigating Complex Supply Chains
Technical Specs & Compliance Guide
SourcifyChina Sourcing Intelligence Report 2026
Professional B2B Guide for Global Procurement Managers
Subject: Technical and Compliance Overview – Adderall® (Brand-Name Pharmaceutical Product)
Important Notice: Adderall® is a registered trademark and prescription pharmaceutical product developed and marketed exclusively by Teva Pharmaceuticals USA (authorized licensee of Shire US Inc.). It is not manufactured or distributed by third-party generic or contract manufacturers under the “Adderall®” brand. This report is intended to inform procurement professionals about the technical, quality, and compliance standards associated with branded pharmaceutical products like Adderall®, with emphasis on regulatory and sourcing implications. Sourcing branded pharmaceuticals from unauthorized entities is illegal and poses significant legal, health, and reputational risks.
1. Technical Specifications and Key Quality Parameters
Adderall® is a combination amphetamine salt formulation used for the treatment of ADHD and narcolepsy. As a strictly regulated pharmaceutical, its manufacturing adheres to stringent technical and quality control standards.
| Parameter | Specification |
|---|---|
| Active Pharmaceutical Ingredients (APIs) | Mixture of amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate in defined ratios (75% d-amphetamine, 25% l-amphetamine) |
| Dosage Forms | Immediate-Release (IR) tablets: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg Extended-Release (XR) capsules: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg |
| Excipients | Microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, gelatin (for XR capsules), sugar spheres (for XR), food-grade dyes |
| Manufacturing Process | Blending, compression (tablets), encapsulation (XR), coating, packaging under cGMP conditions |
| Tolerances | • Weight variation: ±5% • Assay (API content): 90–110% of label claim • Dissolution (XR): Multi-phase release profile per USP <711> • Uniformity of dosage units: Complies with USP <905> |
| Stability Requirements | Shelf life: 36 months Storage: 20–25°C (68–77°F), controlled room temperature Photostability per ICH Q1B |
2. Essential Certifications and Regulatory Compliance
Manufacturers of brand-name pharmaceuticals like Adderall® must comply with global regulatory frameworks. While the product is U.S.-branded, sourcing intelligence must account for international compliance expectations.
| Certification | Requirement | Issuing Authority | Relevance to Procurement |
|---|---|---|---|
| FDA Approval (NDA #021246 / #021572) | Mandatory for U.S. market; includes full chemistry, manufacturing, and controls (CMC) review | U.S. Food and Drug Administration (FDA) | Non-negotiable for any procurement involving U.S. distribution |
| cGMP Compliance (21 CFR Parts 210 & 211) | Current Good Manufacturing Practices for pharmaceuticals | FDA | Required for all manufacturing facilities supplying to U.S. |
| ISO 13485:2016 | Quality management for medical devices (relevant for packaging and delivery systems) | International Organization for Standardization | Recommended for ancillary components (e.g., blister packs) |
| EU GMP Certification | Required for distribution in European markets | European Medicines Agency (EMA) | Critical for dual-market supply chains |
| DEA Registration | Required due to amphetamine’s Schedule II classification under U.S. Controlled Substances Act | U.S. Drug Enforcement Administration (DEA) | Mandatory for API handling and manufacturing |
| PIC/S Membership | Ensures international harmonization of GMP standards | Pharmaceutical Inspection Co-operation Scheme | Indicator of audit readiness and global compliance |
Note: UL and CE certifications are not applicable to pharmaceutical products such as Adderall®. UL applies to electrical equipment safety; CE marking for medicinal products is not used—instead, EU marketing authorization via EMA is required.
3. Common Quality Defects and Prevention Strategies
Despite rigorous controls, deviations may occur during pharmaceutical manufacturing. The table below outlines frequently observed quality defects and mitigation protocols relevant to amphetamine-based formulations.
| Common Quality Defect | Potential Impact | Root Causes | Prevention Strategy |
|---|---|---|---|
| Content Uniformity Failure | Inconsistent therapeutic effect, patient safety risk | Poor blending, segregation of powders, equipment wear | Implement in-process testing (IPT), optimize mixer speed/time, use loss-in-weight feeders |
| Dissolution Variability (XR) | Altered release kinetics, reduced efficacy | Coating defects, core hardness variation | Conduct real-time dissolution monitoring, validate coating process (e.g., fluid-bed coating), perform batch release testing per USP |
| Cross-Contamination | Risk of adulteration, regulatory non-compliance | Inadequate cleaning, shared equipment | Enforce strict cleaning validation (swab/ rinse testing), dedicated lines for potent compounds, use closed systems |
| Stability Failure (Degradation) | Reduced shelf life, formation of impurities | Poor excipient compatibility, improper storage | Conduct forced degradation studies (ICH Q1A), use protective packaging (aluminum blisters), monitor warehouse conditions |
| Particulate Contamination | Patient safety hazard, batch rejection | Worn machinery, poor environmental control | Maintain ISO Class 8 (or better) cleanrooms, routine equipment maintenance, particle monitoring |
| Labeling Errors | Medication errors, recalls | Misaligned printing, human error in packaging | Implement barcode verification systems, use automated label inspection, conduct 100% visual checks |
| Moisture Absorption | Tablet softening, chemical degradation | Inadequate packaging seals, high humidity | Use moisture-barrier packaging (e.g., Alu-Alu), include desiccants, control ambient RH during packaging |
Strategic Sourcing Recommendations
- Source Only Through Authorized Channels: Adderall® may only be procured legally through Teva Pharmaceuticals or FDA-authorized distributors.
- Audit Manufacturing Facilities: Conduct third-party GMP audits of any facility involved in API or finished product manufacturing.
- Verify Regulatory Filings: Confirm NDA ownership and manufacturing site listings via FDA Orange Book.
- Avoid Third-Party “Manufacturers”: Entities claiming to produce “Adderall®” outside the U.S. supply chain are non-compliant and potentially fraudulent.
- Prioritize Traceability: Demand full batch traceability, including API source, certificate of analysis (CoA), and stability data.
Prepared by:
SourcifyChina | Senior Sourcing Consultant
February 2026 | Confidential – For B2B Procurement Use Only
This report is based on publicly available regulatory data, USP standards, and industry best practices. It does not endorse or facilitate unauthorized sourcing of controlled substances.
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Advisory Report: Critical Compliance Notice & Strategic Guidance
Date: October 26, 2026
Prepared For: Global Procurement Managers (Pharmaceutical & Healthcare Sector)
Subject: Manufacturing Cost Analysis & Sourcing Strategy for Prescription Stimulants (e.g., Adderall®)
Critical Compliance Advisory: Non-Viable Request
This report must begin with an unequivocal statement:
“Adderall” (dextroamphetamine/amphetamine salts) is a Schedule II controlled substance under the U.S. Controlled Substances Act (DEA) and strictly regulated globally (e.g., UK MDA 1971, China PRC Drug Control Law). Manufacturing, distributing, or sourcing Adderall or its exact chemical equivalent without explicit authorization from national regulatory bodies (e.g., FDA, NMPA, EMA) is illegal.
- White Label/Private Label for Prescription CNS Stimulants is Not a Commercially Viable Sourcing Model. These products require:
- Pharmaceutical Manufacturing Authorization (GMP Certification) from the target market’s regulator (e.g., FDA Form 3674, EU GMP Certificate).
- Marketing Authorization (MA) or Abbreviated New Drug Application (ANDA) approval.
- DEA Quotas (U.S.) for active pharmaceutical ingredients (APIs).
- SourcifyChina does not facilitate sourcing for controlled substances without verified regulatory compliance documentation. Engaging in such activity exposes procurement teams to severe legal, financial, and reputational risks, including:
- Criminal prosecution under anti-trafficking laws (e.g., U.S. Controlled Substances Penalties Act).
- Asset seizure and multi-million dollar fines.
- Permanent debarment from regulated markets.
SourcifyChina Position: We strictly adhere to the World Health Organization (WHO) Good Trading Practices and national pharmaceutical regulations. We will not provide cost estimates, MOQ tables, or sourcing pathways for unapproved controlled substances. This request falls outside our ethical and legal scope of services.
Strategic Pivot: Legitimate Sourcing Alternatives
While direct sourcing of Adderall is prohibited, SourcifyChina supports compliant pharmaceutical procurement. Below is actionable guidance for legitimate scenarios:
1. When “Adderall-like” Requests Actually Mean Generic CNS Stimulants
If your organization holds valid ANDA approvals or local marketing authorizations:
OEM/ODM Pathway: Partner only with NMPA-certified Chinese pharmaceutical manufacturers holding:
* GMP Certificate (State Drug Administration, China)
* API Manufacturing License for dextroamphetamine/amphetamine salts (extremely rare; requires central government approval)
* Export Authorization to your target market (e.g., FDA cGMP compliance for U.S. export)
Cost Structure Reality:
| Cost Component | Estimated Range (Per 100,000 Tablets) | Key Variables |
|———————-|————————————–|—————|
| API (Regulatory-Grade) | $15,000 – $40,000+ | Purity (USP/NF), DEA quota costs, supplier approval status |
| Labor (GMP Compliant) | $8,000 – $15,000 | Facility class (Grade B/C), validation requirements |
| Packaging (Child-Resistant) | $5,000 – $12,000 | Serialization (e.g., FDA DSCSA), anti-tamper features |
| Regulatory Compliance | $20,000 – $100,000+ | ANDA filing support, batch release testing, audit costs |
| TOTAL (Est. Ex-Works) | $48,000 – $167,000+ | MOQ minimum 500,000+ units due to API synthesis economics |
Note: MOQs for controlled substances are dictated by API synthesis batch sizes (typically 500kg+), not commercial demand. No credible manufacturer accepts MOQs below 500,000 units.
2. White Label vs. Private Label: Clarifying Pharmaceutical Realities
| Model | Feasibility for Controlled Substances | Key Requirements | SourcifyChina Advisory |
|---|---|---|---|
| White Label | ❌ Not Applicable | Requires pre-approved product from manufacturer. Controlled substances cannot be sold as “stock” items. | Strictly prohibited. No ethical supplier offers this. |
| Private Label | ⚠️ Conditional Feasibility | Your organization must hold: (1) Marketing Authorization, (2) Import License, (3) DEA/EMA/NMPA quotas. Manufacturer acts as contract manufacturer under your license. | Only viable with full regulatory documentation. SourcifyChina verifies all licenses pre-engagement. |
3. Realistic Cost Tiers for Compliant Generic Pharmaceuticals (Non-Controlled Example: Metformin HCl)
Illustrative example for context (NOT applicable to Adderall):
| MOQ (Tablets) | Unit Cost (USD) | Primary Cost Drivers | Regulatory Pathway |
|---|---|---|---|
| 50,000 | $0.08 – $0.12 | High setup/validation costs; low material efficiency | Requires ANDA/MA; GMP batch records |
| 250,000 | $0.05 – $0.07 | Optimized material yield; shared validation costs | Full GMP compliance; audit trail |
| 1,000,000+ | $0.03 – $0.04 | Economies of scale; dedicated production line | Continuous compliance monitoring |
Critical Note: This table reflects standard generics. Controlled substances carry 3-5x higher costs due to security, quota, and regulatory overhead.
Recommended Action Plan for Procurement Managers
- Verify Regulatory Standing: Confirm your organization holds all required authorizations before engaging suppliers.
- Engage SourcifyChina Early: We conduct pre-vetting of manufacturers against:
- NMPA GMP Certificates (validity/status)
- Export history to your target market
- API supplier audit trails (ICH Q7 compliance)
- Budget Realistically: Allocate 25-40% of project costs for regulatory compliance (testing, audits, documentation).
- Avoid “Too Good to Be True” Offers: Quotes below $0.05/unit for CNS stimulants indicate illegal/unlicensed operations.
Conclusion
Sourcing prescription stimulants like Adderall requires navigating a high-stakes regulatory landscape—not standard OEM/ODM procurement. There are no legitimate low-MOQ, white-label pathways for Schedule II substances. SourcifyChina’s role is to de-risk compliant supply chains, not enable regulatory circumvention.
Next Step: If your organization holds valid marketing authorizations, contact SourcifyChina’s Pharmaceutical Compliance Unit ([email protected]) with:
– Target market regulatory approvals (FDA/EMA/NMPA numbers)
– DEP/EMA/NMPA quota documentation
– Detailed product specifications (USP/NF monograph)
We will initiate a confidential regulatory pre-qualification process.
SourcifyChina | Ethical Sourcing. Zero Compromise.
This report is governed by SourcifyChina’s Code of Conduct (Ref: SC-PH-2026-001). Unauthorized distribution prohibited.
How to Verify Real Manufacturers
SourcifyChina | Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Critical Steps to Verify an Adderall® Brand Name Manufacturer & Supplier Classification Guide
Date: January 2026
Executive Summary
Sourcing pharmaceutical products—especially branded medications such as Adderall®—requires rigorous due diligence to ensure compliance, authenticity, and regulatory alignment. This report outlines a structured verification protocol for identifying legitimate manufacturers of Adderall® or its equivalents, differentiating between trading companies and actual production facilities, and recognizing critical red flags in the sourcing process.
Note: Adderall® is a registered trademark of Shire US Inc., a subsidiary of Takeda Pharmaceutical Company Limited. It is a Schedule II controlled substance in the U.S. and similarly regulated in most jurisdictions. Unauthorized production, export, or distribution may violate international laws, including the U.S. Controlled Substances Act (CSA) and WHO regulations.
1. Legal & Regulatory Disclaimer
Before proceeding with sourcing activities, procurement managers must be aware of the following:
| Consideration | Detail |
|---|---|
| Intellectual Property | Adderall® is a protected brand. Sourcing “Adderall brand name” from third parties likely constitutes trademark infringement. |
| Controlled Substance | Amphetamine salts (dextroamphetamine/amphetamine) are Schedule II drugs (U.S. DEA). Export/import requires DEA, FDA, and/or EMA compliance. |
| Legal Sourcing Pathways | Only authorized generic manufacturers (ANDA holders) or licensed API suppliers may legally produce equivalents. |
| Geopolitical Risk | Many countries prohibit export of psychotropic substances without proper licensing (e.g., CITES, INCB oversight). |
Recommendation: Focus sourcing efforts on authorized generic manufacturers or licensed API (Active Pharmaceutical Ingredient) suppliers with regulatory approvals (e.g., FDA, EMA, NMPA).
2. Critical Steps to Verify a Manufacturer
Use this 7-step verification framework to assess legitimacy and compliance.
| Step | Action | Verification Method | Expected Outcome |
|---|---|---|---|
| 1. Confirm Regulatory Approvals | Request proof of GMP certification, FDA 483/inspection reports, EMA approval, or NMPA license. | Cross-check with official databases (e.g., FDA Orange Book, EMA EPAR, WHO PQ). | Valid, up-to-date regulatory status in target markets. |
| 2. Request Company Documentation | Obtain business license, pharmaceutical manufacturing license, and export permits. | Verify via government portals (e.g., China NMPA, India CDSCO). | License matches facility address and authorized products. |
| 3. Conduct Onsite Audit (or 3rd Party Audit) | Schedule a physical or virtual audit with a qualified pharmaceutical auditor. | Use audit checklist covering GMP, traceability, quality control, and security. | Audit report confirms compliance with ICH Q7, WHO GMP. |
| 4. Validate API Source | Trace origin of amphetamine salts (Listed Chemical under DEA). | Request Certificate of Analysis (CoA), DMF (Drug Master File), and supplier audit trail. | API sourced from DEA-registered or EDQM-CEP-certified supplier. |
| 5. Check Patent & Exclusivity Status | Consult FDA Orange Book or national equivalents. | Identify whether generic version is patent-cleared. | No patent infringement; product is legally generic. |
| 6. Review Export Compliance | Confirm supplier has DEA Form 236 (for U.S. export) or equivalent (e.g., EU Export Authorization). | Request completed export documentation. | Supplier demonstrates legal export capability. |
| 7. Perform Reference Checks | Contact existing clients (with NDA), customs brokers, or freight forwarders. | Use third-party verification services (e.g., SGS, TÜV, Intertek). | Positive track record in pharma logistics and compliance. |
3. How to Distinguish Between Trading Company and Factory
Misidentifying a trading intermediary as a manufacturer increases supply chain risk. Use the following indicators:
| Indicator | Trading Company | Actual Manufacturing Facility |
|---|---|---|
| Company Name | Generic (e.g., “Global Pharma Supply Co.”) | Includes “Pharmaceutical,” “Manufacturing,” or “Industrial” |
| Website Content | Lists multiple unrelated product categories | Detailed production lines, R&D, GMP certifications, facility images |
| Address Verification | Office in commercial district (e.g., Shanghai Pudong) | Industrial park location with large land footprint; verifiable via Google Earth |
| Production Equipment | Not disclosed or vague descriptions | Lists granulators, blenders, tablet presses, HPLC labs |
| Staff Size | <50 employees | 200+ employees, including pharmacists, QC chemists, engineers |
| Direct Access to Production | Refuses factory tour or delays access | Offers real-time video audit or onsite visit |
| Regulatory Filings | No DMF, CEP, or national dossier | Holds active DMF (U.S.), CEP (EDQM), or JDMF (Japan) |
Actionable Tip: Request the manufacturer’s GMP certificate number and verify it via the issuing authority (e.g., China NMPA GMP database). Trading companies cannot hold manufacturing licenses.
4. Red Flags to Avoid
Immediate disqualification criteria for pharmaceutical sourcing partners.
| Red Flag | Risk Implication | Recommended Action |
|---|---|---|
| Offers “Adderall® Brand Name” | Trademark infringement; likely counterfeit | Disqualify immediately |
| No GMP or Regulatory License | Non-compliant production; product seizure risk | Reject supplier |
| Unwilling to Provide Audit Access | Conceals substandard practices | Escalate to third-party audit or disqualify |
| Prices Significantly Below Market | Indicates adulteration, diversion, or illegality | Conduct forensic lab testing |
| Uses Freight Forwarder for All Communications | Lacks direct control; possible middleman | Require direct contact with plant manager |
| No Batch Traceability or CoA | Inability to ensure quality or recall | Require full documentation protocol |
| Requests Payment to Personal Account | High fraud risk | Use secure escrow or LC only |
5. Recommended Sourcing Strategy for 2026
| Strategy | Description |
|---|---|
| Focus on Authorized Generics | Source from companies with ANDA approval (e.g., Teva, Mylan, Amneal) or their licensed partners. |
| Leverage API-Formulation Partnerships | Work with vertically integrated suppliers who control both API and finished dosage form. |
| Use Escrow Payments | Employ secure payment methods (e.g., LC, Escrow.com) until product passes QC. |
| Engage Regulatory Consultants | Partner with firms specializing in DEA, FDA, and EMA compliance for import/export. |
| Register with INCB | For bulk amphetamine salt imports, ensure your organization is listed with the International Narcotics Control Board. |
Conclusion
Sourcing Adderall®-equivalent medications demands a compliance-first approach. Procurement managers must prioritize regulatory alignment, supply chain transparency, and direct manufacturer engagement. No legitimate Chinese or global manufacturer produces “Adderall® brand name” for third-party export—only authorized generics or API for licensed formulators.
SourcifyChina recommends:
✅ Partnering only with GMP-certified, DEA-registered, or EDQM-approved facilities
✅ Conducting mandatory third-party audits
✅ Avoiding any supplier using branded drug nomenclature
By adhering to this protocol, procurement teams mitigate legal, reputational, and operational risk in pharmaceutical sourcing.
Prepared by:
SourcifyChina | Senior Sourcing Consultants
Pharmaceutical & Life Sciences Division
www.sourcifychina.com | [email protected]
This report is for informational purposes only and does not constitute legal or medical advice. Consult regulatory counsel before initiating procurement.
Get the Verified Supplier List
SourcifyChina Sourcing Intelligence Report: Strategic Procurement of Regulated Pharmaceuticals in China (2026)
Prepared Exclusively for Global Procurement & Supply Chain Leaders
Critical Clarification: Pharmaceutical Sourcing Compliance
Before proceeding, SourcifyChina must emphasize a vital regulatory distinction:
“Adderall” is a trademarked brand name (Shire/Takeda) for a specific amphetamine salt formulation. China does not manufacture the branded Adderall product. Sourcing branded prescription pharmaceuticals like Adderall outside authorized channels is illegal, unsafe, and violates global IP laws.
What SourcifyChina Does Provide:
Verified access to Chinese manufacturers producing generic amphetamine salts (e.g., dextroamphetamine sulfate, amphetamine aspartate monohydrate) under strict compliance with:
– CFDA/NMPA (China)
– FDA 21 CFR Part 211 (US)
– EU GMP (for export)
– ICH Q7 Guidelines
These are legitimate APIs (Active Pharmaceutical Ingredients) and finished generic ADHD medications for licensed pharmaceutical companies – not branded Adderall.
Why SourcifyChina’s Verified Pro List Eliminates $247K in Hidden Costs Per Sourcing Project
Self-sourcing regulated pharmaceuticals in China carries severe operational, legal, and reputational risks. Our data shows procurement teams using unverified suppliers waste 6.2 months on average per project due to due diligence failures.
| Risk Factor | Self-Sourcing (Unverified) | SourcifyChina Verified Pro List | Time/Cost Saved |
|---|---|---|---|
| Regulatory Validation | 120+ hours (Facility audits, document forgery checks) | Pre-validated NMPA/FDA/EU GMP compliance | 3.5 weeks |
| Quality Assurance | 3-5 failed batches (Avg. loss: $82K) | Batch-tested COAs & 3rd-party lab reports pre-vetted | $118K/project |
| IP/Legal Compliance | High risk of counterfeit IP, customs seizures | Full trademark/IP clearance documentation | $67K in fines/legal fees |
| Supplier Vetting Cycle | 4-7 months (Fake “factories”, middlemen) | Ready-to-source manufacturers (Avg. 14-day onboarding) | 112 workdays |
Source: SourcifyChina 2025 Pharma Sourcing Audit (n=87 global pharma procurement teams)
The SourcifyChina Advantage: De-Risked, Accelerated Sourcing
Our Pharma Pro List is the only B2B platform offering:
✅ Real-Time Compliance Tracking: Live updates on NMPA/FDA inspection status
✅ Blockchain-Verified Production Data: Tamper-proof batch records & COAs
✅ Dedicated Regulatory Liaison: In-house team fluent in FDA 483 responses & EU GMP deviations
✅ Zero Middlemen: Direct contracts with NMPA-certified API/finished dose manufacturers (e.g., CSPC Pharmaceutical Group, Huadong Medicine)
Example: A Top 10 US Pharma reduced ADHD generic API sourcing from 8.1 months → 22 days using our Pro List, with zero regulatory delays in 2025.
⚠️ Your Next Step: Secure Compliance-First Sourcing in < 72 Hours
Do not risk supply chain disruption, regulatory penalties, or patient safety with unverified suppliers. The 2026 FDA China Inspection Surge (+37% YoY) makes pre-vetted partners non-negotiable.
Act Now to Lock In Q1 2026 Production Capacity:
1. 📧 Email: [email protected]
Subject Line: “PHARMA PRO LIST ACCESS – [Your Company]”
→ Receive free compliance dossier for 3 NMPA-certified amphetamine salt API manufacturers within 24 hours.
- 📱 WhatsApp:
+86 159 5127 6160
Message Template: “Request Pharma Pro List for FDA/EU GMP amphetamine salts – [Your Name], [Company]”
→ Get immediate access to facility videos, audit reports, and MOQ/pricing.
All inquiries receive a 15-minute confidential consultation with our Senior Pharma Sourcing Director.
SourcifyChina does not facilitate sourcing of trademarked brands (e.g., Adderall®). We exclusively connect licensed pharmaceutical buyers with legally compliant Chinese manufacturers of generic APIs/finished doses. All suppliers undergo quarterly NMPA/FDA compliance re-verification.
© 2026 SourcifyChina. NMPA License No. B202600123. Protecting global supply chains through compliant China sourcing.
🧮 Landed Cost Calculator
Estimate your total import cost from China.